Charles River Laboratories (United Kingdom)
- World rank, 2022–2025
- #14,934 of 28,054 · #23,160 all time
- Rank in United Kingdom
- #539 of 1,094
- Research works
- 257 ▲ 77% vs 2013–17
- Citations
- 4k 15.6 per fractional work
- Top-10% rate
- 19.8% record average 16.5%
- Open access
- 42% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Veterinary, 36.4×. Every wedge is a field page.
- Veterinary 36.4×
- Immunology and Microbiology 9.2×
- Pharmacology, Toxicology and Pharmaceutics 6.0×
- Biochemistry, Genetics and Molecular Biology 4.0×
- Economics, Econometrics and Finance 3.7×
- Chemistry 2.6×
- Neuroscience 1.9×
- Medicine 1.8×
- Nursing 1.1×
- Business, Management and Accounting 0.6×
- Environmental Science 0.4×
- Chemical Engineering 0.3×
- Agricultural and Biological Sciences 0.2×
- Decision Sciences 0.2×
- Physics and Astronomy 0.2×
- Health Professions 0.2×
- Social Sciences 0.2×
- Psychology 0.1×
- Engineering 0.1×
- Mathematics 0.1×
- Computer Science 0.1×
- Materials Science 0.1×
- Dentistry 0.1×
Who are the top researchers at Charles River Laboratories (United Kingdom)?
Ranked on the composite score, Jim Hillier and Michele Pistollato lead among researchers whose main affiliation is Charles River Laboratories (United Kingdom).
- 1 Jim Hillier United Kingdom · #195,303 worldwide 30 citations · 35 works
- 2 Michele Pistollato United Kingdom · #1,616,906 worldwide 2 citations · 19 works
Which keywords describe research at Charles River Laboratories (United Kingdom)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Cancer, Cancer Immunotherapy, Cost-effectiveness Analysis, Health Utility Measures, Immunity, Monoclonal Antibodies, Innate Immunity and Ethical Considerations.
- Mass Spectrometry
- Therapeutic Antibodies
- Pharmaceutical Industry
- Immunogenicity
- Generic Drugs
- Chimeric Antigen Receptor
- Biopharmaceuticals
- Immunotoxicity
- spirometry
- COPD
- Toxicology
- Global Burden
- Mitochondrial Dysfunction
- Immune System
- ARRIVE Guidelines
- Monoclonal Antibodies
- Oxidative Stress
- Health Utility Measures
- Quality of Life
- Inflammation
- Cancer
- Cancer Immunotherapy
- Cost-effectiveness Analysis
- Immunity
- Innate Immunity
- Ethical Considerations
- Animal Research Reporting
- Immunotherapy
- Publication Bias
- Neurotoxicity
- Tumor Microenvironment
- Respiratory
- Histopathology
- Targeted Therapy
- CAR T Cells
- Drug Development Costs
- Glycosylation
- Metabolic Regulation
- Pharmacokinetics
- Transcriptional Regulation
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Cancer5▲ 4.8×19 topics
- Inflammation4▲ 2.4×19 topics
- Cancer Immunotherapy3▲ 25×2 topics
- Quality of Life3▲ 2.7×2 topics
- Cost-effectiveness Analysis3▲ 44×1 topic
- Health Utility Measures3▲ 44×1 topic
- Immunity3▲ 9.2×4 topics
- Oxidative Stress3▲ 2.2×16 topics
- Innate Immunity2▲ 9.9×6 topics
- Monoclonal Antibodies2▲ 36×3 topics
- Ethical Considerations2▲ 9.0×4 topics
- ARRIVE Guidelines2▲ 236×1 topic
- Animal Research Reporting2▲ 236×1 topic
- Immune System2▲ 12×3 topics
- Immunotherapy2▲ 4.0×5 topics
- Mitochondrial Dysfunction2▲ 9.5×5 topics
- Publication Bias2▲ 62×3 topics
- Global Burden2▲ 4.7×2 topics
- Neurotoxicity2▲ 20×3 topics
- Toxicology2▲ 15×3 topics
- Tumor Microenvironment2▲ 5.5×4 topics
- COPD2▲ 35×1 topic
- Respiratory2▲ 25×2 topics
- spirometry2▲ 35×1 topic
- Histopathology2▲ 120×1 topic
- Immunotoxicity2▲ 473×1 topic
- Targeted Therapy2▲ 10.0×5 topics
- Biopharmaceuticals2▲ 40×2 topics
- CAR T Cells2▲ 28×1 topic
- Chimeric Antigen Receptor2▲ 28×1 topic
- Drug Development Costs2▲ 80×1 topic
- Generic Drugs2▲ 80×1 topic
- Glycosylation2▲ 19×3 topics
- Immunogenicity2▲ 47×2 topics
- Metabolic Regulation2▲ 12×4 topics
- Pharmaceutical Industry2▲ 57×2 topics
- Pharmacokinetics1▲ 7.6×5 topics
- Therapeutic Antibodies1▲ 27×2 topics
- Transcriptional Regulation1▲ 12×6 topics
- Mass Spectrometry1▲ 12×2 topics
Which research topics does Charles River Laboratories (United Kingdom) publish most on?
By volume in 2022–2025: Health Systems, Economic Evaluations, Quality of Life, Animal testing and alternatives, Chronic Obstructive Pulmonary Disease (COPD) Research and Immunotoxicology and immune responses.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 3 works
- 2 Animal testing and alternatives Small Animals 2 works
- 3 Chronic Obstructive Pulmonary Disease (COPD) Research Pulmonary and Respiratory Medicine 2 works
- 4 Immunotoxicology and immune responses Immunology 2 works
- 5 CAR-T cell therapy research Oncology 2 works
- 6 Pharmaceutical Economics and Policy Economics and Econometrics 2 works
- 7 Immunotherapy and Immune Responses Immunology 1 works
- 8 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 9 Vaccine Coverage and Hesitancy Health 1 works
- 10 Economic and Financial Impacts of Cancer Economics and Econometrics 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Charles River Laboratories (United Kingdom)'s research output changed?
Output in 2018–2022 was 77% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Tranent
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.